Boston Scientific's endoscope business grows by over 20 percent
Although endoscope sales at US-based Boston Scientific have had a good year in 2021, the company has seen its bottom line halved during its latest financial year.
by ULRICH QUISTGAARD, translated by daniel pedersen
In 2021, Boston Scientific added 20.3 percent to its endoscopy business, and sold endoscopes for USD 2.14bn, compared to 2020’s result of USD 1.78bn, the company reports in its full-year 2021 financial report.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
